Skip to main content

Table 1 Baseline clinical and laboratory findings

From: Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases

Clinical parameter

N = 21

Age, years, median (range)

60 (33–75)

Gender

 

 Male, n (%)

7 (33)

 Female, n (%)

14 (67)

Tumor origin

 

 Colon, n (%)

19 (90)

 Rectum, n (%)

2 (10)

Primary in place, n (%)

13 (62)

Extrahepatic disease, n (%)

14 (67)

Extrahepatic disease sites

 

 Lungs

8

 Lymph nodes

5

 Peritoneum

1

 Adrenal gland

1

Prior systemic therapy

 

 5-FU, oxaliplatin, irinotecan, and bevacizumab

21 (100%)

 EGFR inhibitor

9 (43)

 Regorafenib

4 (19)

ECOG PS

 

 0 / 1

6 / 15

Liver replacement, n (%)

 

  < 25%

10 (48)

 26–50%

11 (52)

  1. Abbreviations: 5-FU 5-fluorouracil, ECOG PS Eastern Cooperative Oncology Group Performance Status